Summary, slides, & video from the CARB-X + GARDP Bootcamps, 5-8 Sep 2017 ASM-ESCMID Conference

This note was updated on 12 Jan 2018 to provide links to the videos from the bootcamp sessions.

Dear All: 

GARDP + CARB-X have this week hosted Antibiotic Bootcamps #1, #2, and #3 at the ASM-ESCMID conference on antibiotic R&D. There were nearly 350 people registered for the full meeting with good attendance at each Bootcamp. 

Bootcamp #1 (Lynn Silver, Tom Dougherty, Sherman Waddell, and John Tomayko) covered the question of finding interesting start points for R&D: What makes a good hit? What makes a good lead? Who were Lipinski and Oprea and why should you care? Watch the video.

Bootcamp #2 (Tim Keutzer, Evan Hecker, and Mike Young, and Andrew Barlow) took us through the challenges of CMC (Chemistry, Manufacturing, and Controls). Building on the hypothetical case of drug X-1 used for last year’s FDA workshop on developing narrow-spectrum antibiotics, the speakers showed clearly how CMC considerations must be front and center from a very early stage in any development program. Watch the video.

Bootcamp #3 (Erika Matuschek, Kevin Krause, Robin Patel, and Judith Steenbergen) took us through the mysteries of susceptibility testing. It was a soup-to-nuts review that should be reviewed along with the materials from the 13 Sep 2017 FDA-CDRH workshop on diagnostic devices for detecting antimicrobial susceptibility & resistance. Watch the video.

The speakers have also agreed to share their slides.This .zip file (4.4MB) contains the talks from Bootcamps #1 and #2 (note that Bootcamp #2 is provided as a single presentation). And, here is the .zip file (2.3 MB) for the slides from Bootcamp #3. See links after my signature to the individual files.

Again, many thanks to the speakers and to ASM-ESCMID for enabling GARDP & CARB-X to host these events!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Note: If you have trouble unzipping the .zip files, here are links to the individual files provided by the speakers:

Upcoming meetings of interest to the AMR community:

  • 18 Jan 2018 (Geneva): Release of the First Annual Progress Report in support of the UN Sustainable Development Goals (SDG 3 in particular) by the AMR Industry Alliance
  • 12-14 Feb 2018 (Baltimore): ASM Biothreats Conference
  • 28 Feb 2018 (Brussels): Deadline for responses to IMI2 Call 13 (Topic 3) on AMR diagnostics
  • 11-16 Mar 2018 (Ventura Beach): Gordon Research Conference on Antibacterial Discovery
  • 21-24 Apr 2018 (Madrid): ECCMID
  • [NEW] 4-7 Jun 2018 (Boston): BIO (multiple AMR-focused sessions are expected)
  • 7-11 Jun 2018 (Atlanta): ASM Microbe
  • 22-27 Jul 2018 (Bryant University, Smithfield, RI): Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture
  • [Don’t miss this one] 4-7 Sep 2018 ESCMID-ASM Conference (#3) on Drug Development for AMR (Lisbon, Portugal) (initial flyer)
  • 6-14 Oct 2018 International Course on Antibiotics and Resistance (ICARe, Les Pensières, Annecy, France) (link to 2017 program — details pending for 2018)

Share

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1 Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and dig in!) The Center for Global Development have released a blog post and a paper estimating the potential impact of the PASTEUR Act.

Five FDA RFPs! Antifungal animal models, MIC breakpoints, and more!

Dear All, I just today learned that FDA have posted their FY 2023 funding opportunities. All the details are on this webpage and I’m just going to reproduce the text below my signature for your reference. I’ll also add a few details in italics. Lots of good opportunities here! –jr John H. Rex, MD |

WAAW! Must-Read Article, A Quiz, A Video, A Call to Action

Notes: Newsflash … BARDA have opened their long-running BAA-18-100-SOL-00003 to include support for antifungal agents. Search for “antifungal” in the posted .pdf to find the text. The first deadline for proposals is 15 Dec 2022 and further deadlines will doubtless follow: as shown on page 9, this BAA has offered 4 deadlines/year since 2018!  Dear All, In

Fireside Chat with AMR Action Fund CIO Martin Heidecker

Dear All, Ahead of World Antimicrobial Awareness Week, I sat down with AMR Action Fund Chief Investment Officer Martin Heidecker for a Fireside Chat. It was a fabulous conversation that covered everything from how the Fund’s investment process works to what it’s looking for in portfolio companies to broader investment trends in the AMR space.  As

Scroll to Top